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Introduction: Everolimus, a mammalian target of Rapamycin inhibitor, has recently been approved for the treatment
of metastatic estrogen receptor-positive breast cancer, in combination with exemestane at a daily dose of 10mg. In the
literature, few cases of acute kidney injury have been reported related to everolimus use, but none of them in a patient
with breast cancer as we report here. Our case report of acute kidney injury demonstrates the potential nephrotoxic
effects of everolimus therapy, necessitating close monitoring of renal function prior to, during and after discontinuation
of the drug.
Case presentation: We report the first published case of acute kidney injury shortly after initiation of exemestane
and everolimus for metastatic breast cancer resistant to letrozole in a 69-year-old Caucasian woman, initially treated for
a stage IIB estrogen receptor-positive breast cancer in 1997. Within 2 weeks of therapy, she developed grade 1 to
2 diarrhea, lower extremity edema, lethargy, and anorexia. After 4 weeks of therapy, her blood pressure was 85/
59mmHg and she lost 4kg bodyweight. Her serum creatinine was 3.34mg/dL. Everolimus was stopped, and
she was hospitalized for rehydration. Her serum creatinine levels peaked at 8.85mg/dL 8 days after treatment
discontinuation, with a calculated creatinine clearance of 7mL/minute. Dialysis was not required. A month later, her
serum creatinine levels slowly dropped to 2.26mg/dL but did not return to baseline. No re-challenge of everolimus was
attempted.
Conclusions: Extreme vigilance should be used when prescribing everolimus for metastatic breast cancer. Although
the exact cause of acute kidney injury in our case is unknown, dehydration must be avoided and renal function closely
monitored after initiating therapy. Spontaneous recovery after drug discontinuation is possible.
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Everolimus, a mammalian target of rapamycin (mTOR)
inhibitor, has recently been approved by the US Food
and Drug Administration and the European Medicines
Agency, in combination with exemestane, for the treat-
ment of hormone receptor-positive, human epidermal
growth factor receptor 2-negative advanced breast cancer
in postmenopausal women without symptomatic visceral
disease and after recurrence or progression following a
non-steroidal aromatase inhibitor. Everolimus is given
ata daily dose of 10mg continuously. Renal function
impairment and a few cases of acute kidney injury (AKI)
have been related to everolimus for non-breast cancer* Correspondence: francesca.donders@gmail.com
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unless otherwise stated.indications [1,2]. We describe here the second reported
case in the literature of AKI in a patient with breast cancer
treated with everolimus. We discuss the pathophysiology
and relevant literature to conclude that everolimus can
cause a serious decline in renal function. Kidney function
should be closely monitored prior to, during, and after
discontinuing treatment.
Case presentation
A 69-year-old Caucasian woman was treated for stage
IIB estrogen receptor (ER)-positive left breast cancer in
1997. Besides two cerebrovascular accidents with full
recovery, she had no significant comorbidities apart
from chronic atrial fibrillation for which she received
treatment with a vitamin K antagonist. In November
2010, she developed metastatic lesions in bone, lymph
nodes, lung and liver. Over a 2-year period she consecutivelyl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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oxifen for 6 months, letrozole for 11 months and abira-
terone for 5 months. In December 2010 she underwent
palliative radiotherapy for painful lytic lesions; she
received intravenous zoledronic acid therapy monthly.
Maintenance home therapy included simvastatin, biso-
prolol, losartan, lormetazepam, and phenprocoumon.
Exemestane 25mg plus everolimus 10mg were started in
November 2012, 1 month after she switched from the
vitamin K antagonist to low-molecular-weight heparin
because of possible drug interactions with everolimus,
since metabolization of phenprocoumon occurs through
the CYP3A4 pathway.
At baseline, on October 19 of 2012, her renal function
was normal based on her serum creatinine (0.87mg/dL;
normal range, NR, 0.51 to 0.95) and estimated glomeru-
lar filtration rate (68mL/minute/1.73m2). On November
9 of 2012 the first cycle of everolimus was started. Her
blood creatinine level was 0.90mg/dL. At the time of
her first dose of everolimus an echocardiography was
performed and showed no direct signs of left or right
ventricular dysfunction. On December 7 she came for
her week four visit to collect a second cycle of tablets,
but a low blood pressure of 85/59mmHg was measured;
she had lost 4kg bodyweight and an increase in serum cre-
atinine to 3.34mg/dL was noted in the laboratory results.
She reported that after 2 weeks of therapy she developed
grade 1 to 2 diarrhea, leg edema, lethargy, and anorexia.
She had another episode of watery diarrhea during the
preceding week, but it had resolved by the time of her
second dose. Everolimus was stopped and she was
hospitalized and started on intravenous fluids because
of signs of dehydration and possible secondary acute
tubular necrosis (ATN). A new echocardiography showedFigure 1 The evolution serum creatinine levels (in mg/dL) in this pati
November 9 and discontinuation on December 20 of 2012.no changes in cardiac function. In the following days, des-
pite rehydration therapy with 1.5L/day of sodium chloride,
her serum creatinine levels further increased. Serum
creatinine levels peaked at 8.85mg/dL, with a calculated
creatinine clearance of 7mL/minute, 8 days after treat-
ment discontinuation. A renal ultrasound excluded
post-renal causes of acute renal failure and showed nor-
mal sized kidneys. Her C-reactive protein levels were
elevated to 240mg/dL (NR≤5) without leukocytosis or
fever. There was no neutropenia. A chest X-ray showed
bilateral minimal basal pulmonary effusions, but no
infiltrates suspicious for infection were observed. Urine
and hemocultures remained sterile. Urine microscopy
showed rare granular casts and <10% of dysmorphic eryth-
rocytes and few leukocytes. A 24-hour urine collection
showed a proteinuria of 0.71g/24 hours (NR≤0.15); no
renal biopsy was performed. On admission, immuno-
logical screening was negative and everolimus blood levels
were 40ng/mL 4 hours post-dose. Dialysis was not
required and 1 month after treatment discontinuation,
her serum creatinine levels slowly dropped to 2.26mg/dL
but never returned to baseline (Figure 1). No re-challenge
of everolimus was attempted.
Discussion
Two recent articles highlight nephrotoxicity associated
with the use of mTOR inhibitors. Izzedine et al. (2013)
reported the first four cases of AKI while Choueiri et al.
(2013) considered AKI in all placebo-controlled trials to
be the second most cause of fatal adverse events during
early stages of therapy; however, in these studies, the
patients did not have breast cancer [1,2]. In the BOLERO-
2 study, which showed a significant progression-free
survival advantage of everolimus plus exemestane overent with breast cancer, after starting everolimus treatment on
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the 482 patients with breast cancer [3].
First of all we need to take into account the cardiovas-
cular comorbidity and her age in possibly overestimating
renal functioning at baseline by only measuring serum
creatinine. Most likely the AKI occurred following severe
volume depletion, inducing ATN, which in turn required
intact intracellular mTOR to enable tubular regener-
ation, in support of the autophagy theory [4]. A possible
interaction of mTOR inhibitors with simvastatin, leading
to a toxic dose of simvastatin and/or everolimus, through
a common (cytochrome) metabolic pathway could have
also played a role. Blood everolimus levels were 40ng/mL
4 hours after drug administration. This concentration falls
within the expected range, in comparison to the results
of the pharmacokinetic (PK) analyses of BOLERO-2,
given that the median peak concentration 1 to 2 hours
post-dose is 59.7 ±16.9 (standard deviation) ng/mL and the
median trough concentration (Cmin) is 15.6 ±12.2ng/mL.
Statin levels in our case were not measured. Co-
administration of statins with everolimus could have
induced rhabdomyolysis. Creatinine kinase levels, how-
ever, were only mildly raised (320U/L) and too low to be
causal. Substrates of CYP3A4, such as HMG-CoA reduc-
tase inhibitors, are not expected to affect blood levels of
everolimus. In BOLERO-2, 23% of everolimus-treated
patients (versus 17% of patients treated with exemestane
alone) received HMG-CoA reductase inhibitors as
co-medications while AKI was reported in only one
case in BOLERO-2 [3]. Exemestane itself is also metab-
olized by CYP3A4 and although everolimus, being a
CYP3A4 inhibitor, increases exemestane levels, exe-
mestane does not seem to affect everolimus blood
levels [5]. However, PK analyses in BOLERO-2 showed
that co-administration of exemestane had no effect
on blood levels and overall exposure to everolimus.
Co-administering everolimus with strong CYP3A4
inhibitors has been shown to increase Cmin and thus
exposure to everolimus at maximum by 20% without
having an effect on toxicity whatever grade [6]. It
remains possible that intrarenal concentrations of everoli-
mus or its pharmacodynamic (PD) effect are significantly
affected by co-administration of exemestane despite
acceptable blood concentrations [7].
There is now extensive experience with everolimus in
several tumor types, as well as experience with other
mTOR inhibitors. Much of this information comes from
large databases from the manufacturer and several clinical
trials. The safety profile of everolimus in the BOLERO-2
study is very similar to the profile reported in other
clinical trials. Adverse events with everolimus are
mostly mild to moderate in severity. With careful moni-
toring, early identification, and appropriate intervention –
including dose interruption or reduction – they aremanageable and generally reversible. The serious adverse
event rate in BOLERO-2 was 23% versus 12% in the
exemestane-alone arm [3].
It is unclear whether it is necessary to monitor everoli-
mus blood levels during treatment, as there is no identi-
fied relationship between blood levels obtained after a
10mg everolimus dose and occurrence of specific toxic-
ities. Following a 10mg oral dose, the drug exposure
ranges are well characterized, as described above.
Another question is whether a lower dose should be
started. The efficacious dose used in phase 3 trials was
10mg. Initial PK and PD studies showed that 10mg
produces more complete target inhibition than 5mg.
One study has reported the use of a stepwise dose-
escalation schedule of everolimus in combination with
paclitaxel, starting with 2.5mg and escalating to 5mg
(full combination dose) over 2 weeks [8]. Efficacy and
safety studies utilizing this approach starting with 5mg
everolimus and escalating to 10mg in combination
with exemestane for ER-positive breast cancer are
currently under consideration. Secondly, in cases when
concomitant drugs, known to interfere with the metab-
olism of everolimus (CYP3A4), are initiated, monitor-
ing of blood levels could prove to be advantageous.
Renal function seems to decrease with increasing low
doses of everolimus (3mg versus 1.5mg) [9]. The adverse
event profile among elderly patients in BOLERO-2 was
generally comparable to that of younger patients [10].
However, deaths due to any cause within 28 days of the
last everolimus dose occurred in 6% of patients ≥65 years
of age compared to 2% in patients <65 years of age and
adverse events leading to permanent treatment discon-
tinuation occurred in 33% of patients ≥65 years of age
compared to 17% in patients <65 years of age. Careful
monitoring of older patients is therefore recommended.
Conclusions
Despite an overall improved effect on kidney function
following kidney transplantation and in specific types of
renal diseases, a dose-dependent renal impairment has
previously been reported with much lower doses of
everolimus in transplant patients [9,11]. Extreme vigi-
lance should be used when prescribing everolimus for
metastatic breast cancer. Although the exact cause of
AKI in our case is unknown, dehydration should be
avoided and renal function closely monitored prior to
and soon after initiating everolimus 10mg.
Consent
The patient is deceased. Written informed consent was
obtained from the patient’s next of kin for publication of
this case report and accompanying images. A copy of
the written consent is available for review by the Editor-
in-Chief of this journal.
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